Physician profile
Fortune O Alabi
NPI 1124025309
$587,333.26
in general payments reported to CMS, 2019-2025
70 companies · $81K in 2025
The $81K reported for 2025 was more than what 99% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $65K · 2020: $46K · 2021: $70K · 2022: $131K · 2023: $97K · 2024: $98K · 2025: $81K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $177K · Honoraria: $29K · Food and Beverage: $28K · Consulting Fee: $24K · Travel and Lodging: $16K · Education: $454 · Gift: $40.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $177,450.07 |
| Honoraria | $29,362.50 |
| Food and Beverage | $28,052.38 |
| Consulting Fee | $24,238.00 |
| Travel and Lodging | $16,284.16 |
| Education | $453.76 |
| Gift | $40.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $169,991.16 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111,000.47 | 2019-2025 | Ofev, Jascayd, Stiolto Respimat |
| Mallinckrodt Hospital Products INC. | $79,431.86 | 2020-2025 | Acthar |
| Ani Pharmaceuticals, INC. | $38,380.50 | 2023-2025 | Purified Cortrophin Gel |
| E.R. Squibb & Sons, L.L.C. | $27,131.52 | 2019-2024 | Eliquis |
| United Therapeutics Corporation | $25,852.38 | 2019-2025 | Tyvaso, Tyvaso, Orenitram |
| Glaxosmithkline, LLC. | $24,566.43 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $23,692.61 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $20,728.49 | 2019-2025 | Dupixent |
| Insmed, INC. | $15,377.01 | 2019-2025 | Arikayce, Brinsupri |
| Amgen INC. | $8,511.27 | 2022-2025 | Tezspire |
| Actelion Pharmaceuticals US, INC. | $7,713.46 | 2019-2025 | Uptravi, Opsumit |
| Pfizer INC. | $6,886.20 | 2019-2023 | |
| Genentech USA, INC. | $5,815.06 | 2019-2024 | Xolair |
| Verona Pharma, INC. | $5,782.57 | 2025 | Ohtuvayre |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $2,011.91 | 2019-2025 | |
| Viiv Healthcare Company | $1,600.00 | 2019 | |
| Philips North America LLC | $1,403.26 | 2019-2024 | (Ak6) Vest Therapy |
| Novartis Pharmaceuticals Corporation | $1,281.04 | 2019-2022 | |
| Grifols USA, LLC | $1,027.32 | 2019-2025 | Prolastin-C Liquid |
| Harmony Biosciences LLC | $823.80 | 2020-2025 | |
| Edwards Lifesciences Corporation | $808.79 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $647.67 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $561.19 | 2020-2025 | Glassia, Cuvitru |
| Mylan Specialty L.P. | $437.49 | 2019-2024 | Yupelri |
| Paratek Pharmaceuticals, INC. | $409.52 | 2019-2025 | Nuzyra |
| Pulmonx Corporation | $395.02 | 2022-2024 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Axsome Therapeutics, INC. | $373.62 | 2022-2025 | Sunosi |
| Regeneron Pharmaceuticals, INC. | $342.66 | 2022-2025 | Dupixent |
| Zoll Respicardia, INC. | $312.33 | 2021 | |
| Sanofi-Aventis U.S. LLC | $286.13 | 2021-2022 | |
| Avadel Cns Pharmaceuticals, LLC | $272.16 | 2023-2025 | Lumryz |
| Ethicon INC. | $269.76 | 2021-2023 | Monarch Platform |
| Merck Sharp & Dohme LLC | $260.33 | 2021-2025 | Winrevair, Zerbaxa, Dificid |
| Inspire Medical Systems, INC. | $248.02 | 2023-2025 | Inspire |
| Vapotherm INC | $225.89 | 2019-2023 | Vapotherm |
| Allergan, INC. | $225.49 | 2019 | |
| Genentech, INC. | $223.60 | 2021 | |
| Electromed, INC. | $220.73 | 2021-2025 | Smartvest |
| Biomerieux INC | $189.48 | 2019 | |
| Sunovion Pharmaceuticals INC. | $172.91 | 2019-2020 | |
| La Jolla Pharmaceutical Company | $128.60 | 2023 | Giapreza |
| Gilead Sciences, INC. | $128.35 | 2021-2023 | |
| Idorsia Pharmaceuticals US INC | $124.65 | 2023 | Quviviq |
| Sandoz INC. | $121.05 | 2023-2025 | Treprostinil |
| Vertex Pharmaceuticals Incorporated | $119.50 | 2025 | |
| Janssen Pharmaceuticals, INC | $114.92 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $100.79 | 2020-2023 | Airduo Digihaler |
| Vifor Pharma, INC. | $81.46 | 2024-2025 | Zemaira |
| Grifols Shared Services North America, INC. | $79.87 | 2022 | |
| Viatris Specialty LLC | $74.92 | 2025 | Yupelri |
| Fisher & Paykel Healthcare INC | $73.95 | 2020-2025 | Fisher & Paykel Healthcare |
| Mallinckrodt Enterprises LLC | $45.54 | 2019 | |
| Itamar Medical INC | $39.48 | 2021-2023 | Watchpatone |
| Inogen, INC. | $34.65 | 2022 | |
| Liquidia Technologies, INC. | $24.51 | 2025 | Yutrepia |
| Kite Pharma, INC. | $21.97 | 2021 | |
| Tactile Systems Technology INC | $17.77 | 2024 | Entre Plus, Flexitouch Plus |
| Breas Medical, INC. | $17.10 | 2023 | Vivo 45 Ls |
| Hikma Pharmaceuticals USA | $17.04 | 2023 | Ryaltris |
| Resmed Corp | $16.86 | 2023 | |
| Portola Pharmaceuticals, LLC | $16.23 | 2019 | |
| Phadia US INC. | $16.09 | 2021 | |
| Alk-Abello, INC | $13.51 | 2019 | |
| Boston Scientific Corporation | $13.34 | 2022 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2,007.97 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fortune Alabi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.